REFERENCES
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63.
2. Giaquinto AN, Sung H, Newman LA, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74:477-95.
3. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
4. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109-19.
6. Karami Fath M, Azargoonjahromi A, Kiani A, et al. The role of epigenetic modifications in drug resistance and treatment of breast cancer. Cell Mol Biol Lett. 2022;27:52.
7. Ponting CP, Haerty W. Genome-wide analysis of human long noncoding RNAs: a provocative review. Annu Rev Genomics Hum Genet. 2022;23:153-72.
8. Shi K, Liu T, Fu H, Li W, Zheng X. Genome-wide analysis of lncRNA stability in human. PLoS Comput Biol. 2021;17:e1008918.
9. Mattick JS, Amaral PP, Carninci P, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24:430-47.
10. Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA. Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther. 2022;7:121.
11. Zhou W, Xu X, Cen Y, Chen J. The role of lncRNAs in the tumor microenvironment and immunotherapy of melanoma. Front Immunol. 2022;13:1085766.
12. Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36:5661-7.
14. Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17:205-11.
15. Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965-81.
16. Kichi ZA, Soltani M, Rezaei M, Shirvani-Farsani Z, Rojhannezhad M. The emerging role of EMT-related lncRNAs in therapy resistance and their applications as biomarkers. Curr Med Chem. 2022;29:4574-601.
17. Pan G, Liu Y, Shang L, Zhou F, Yang S. EMT-associated microRNAs and their roles in cancer stemness and drug resistance. Cancer Commun. 2021;41:199-217.
18. Jiang N, Zhang X, Gu X, Li X, Shang L. Progress in understanding the role of lncRNA in programmed cell death. Cell Death Discov. 2021;7:30.
19. Ye P, Feng L, Shi S, Dong C. The mechanisms of lncRNA-mediated multidrug resistance and the clinical application prospects of lncRNAs in breast cancer. Cancers. 2022;14:2101.
20. Zhang JN, Yi ZL, Zhou XR, Liu SS, Liu H. Dual role of lncRNA OTUD6B-AS1 in immune evasion and ferroptosis resistance: a prognostic and therapeutic biomarker in breast cancer. Noncoding RNA Res. 2025;14:156-65.
21. Tong X, Yu Z, Xing J, et al. LncRNA HCP5-encoded protein regulates ferroptosis to promote the progression of triple-negative breast cancer. Cancers. 2023;15:1880.
22. Li C, Zhang Y. Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer. BMC Med Genom. 2023;16:158.
23. Wu JH, Cheng TC, Zhu B, Gao HY, Zheng L, Chen WX. Identification of cuproptosis-related gene SLC31A1 and upstream LncRNA-miRNA regulatory axis in breast cancer. Sci Rep. 2023;13:18390.
24. Du T, Shi Y, Xu S, Wan X, Sun H, Liu B. Long non-coding RNAs in drug resistance of breast cancer. Onco Targets Ther. 2020;13:7075-87.
25. Wang Y, Wang Y, Qin Z, et al. The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer. Expert Opin Drug Metab Toxicol. 2021;17:291-306.
26. Blackley EF, Loi S. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC). Breast. 2019;48 Suppl 1:S44-8.
27. Huynh MM, Pambid MR, Jayanthan A, Dorr A, Los G, Dunn SE. The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials. Expert Opin Investig Drugs. 2020;29:1199-208.
28. Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. Nature. 2012;489:101-8.
29. Chen Z, Pan T, Jiang D, et al. The lncRNA-GAS5/miR-221-3p/DKK2 Axis modulates ABCB1-mediated adriamycin resistance of breast cancer via the wnt/β-catenin signaling pathway. Mol Ther Nucleic Acids. 2020;19:1434-48.
30. Zhang H, Zhang XY, Kang XN, Jin LJ, Wang ZY. LncRNA-SNHG7 enhances chemotherapy resistance and cell viability of breast cancer cells by regulating miR-186. Cancer Manag Res. 2020;12:10163-72.
31. Liu PF, Farooqi AA, Peng SY, et al. Regulatory effects of noncoding RNAs on the interplay of oxidative stress and autophagy in cancer malignancy and therapy. Semin Cancer Biol. 2022;83:269-82.
32. Kacso TP, Zahu R, Tirpe A, Paslari EV, Nuțu A, Berindan-Neagoe I. Reactive oxygen species and long non-coding RNAs, an unexpected crossroad in cancer cells. Int J Mol Sci. 2022;23:10133.
33. Baylie T, Jemal M, Baye G, et al. The role of telomere and telomerase in cancer and novel therapeutic target: narrative review. Front Oncol. 2025;15:1542930.
34. Dratwa M, Wysoczańska B, Łacina P, Kubik T, Bogunia-Kubik K. TERT-regulation and roles in cancer formation. Front Immunol. 2020;11:589929.
35. Lu L, Zhang C, Zhu G, et al. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Res. 2011;13:R56.
36. Lipinska N, Romaniuk A, Paszel-Jaworska A, Toton E, Kopczynski P, Rubis B. Telomerase and drug resistance in cancer. Cell Mol Life Sci. 2017;74:4121-32.
37. Cayuela ML, Flores JM, Blasco MA. The telomerase RNA component Terc is required for the tumour-promoting effects of Tert overexpression. EMBO Rep. 2005;6:268-74.
38. Hu W, Tan C, He Y, Zhang G, Xu Y, Tang J. Functional miRNAs in breast cancer drug resistance. Onco Targets Ther. 2018;11:1529-41.
39. Wang X, Pei X, Guo G, et al. Exosome-mediated transfer of long noncoding RNA H19 induces doxorubicin resistance in breast cancer. J Cell Physiol. 2020;235:6896-904.
40. Zheng Z, Chen M, Xing P, Yan X, Xie B. Increased expression of exosomal AGAP2-AS1 (AGAP2 antisense RNA 1) in breast cancer cells inhibits trastuzumab-induced cell cytotoxicity. Med Sci Monit. 2019;25:2211-20.
41. Xu CG, Yang MF, Ren YQ, Wu CH, Wang LQ. Exosomes mediated transfer of lncRNA UCA1 results in increased tamoxifen resistance in breast cancer cells. Eur Rev Med Pharmacol Sci. 2016;20:4362-8.
42. Kansara S, Pandey V, Lobie PE, Sethi G, Garg M, Pandey AK. Mechanistic involvement of long non-coding RNAs in oncotherapeutics resistance in triple-negative breast cancer. Cells. 2020;9:1511.
43. Veneziano D, Marceca GP, Di Bella S, Nigita G, Distefano R, Croce CM. Investigating miRNA-lncRNA interactions: computational tools and resources. In: Laganà A, editor. MicroRNA target identification. New York: Springer; 2019. pp. 251-77.
44. Guz M, Jeleniewicz W, Cybulski M. Interactions between circRNAs and miR-141 in cancer: from pathogenesis to diagnosis and therapy. Int J Mol Sci. 2023;24:11861.
45. Li Z, Qian J, Li J, Zhu C. Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway. Exp Ther Med. 2019;18:435-42.
46. Suicmez M, Namalir G, Konus M, Ozdil H. Silencing of lncRNA UCA1 reverses doxorubicin resistance of breast cancer through inhibiting PI3K/AKT/mTOR signaling pathway. ChemistrySelect. 2024;9:e202400819.
47. Lei C, Li S, Fan Y, et al. LncRNA DUXAP8 induces breast cancer radioresistance by modulating the PI3K/AKT/mTOR pathway and the EZH2-E-cadherin/RHOB pathway. Cancer Biol Ther. 2022;23:1-13.
48. Sadeghalvad M, Mansouri K, Mohammadi-Motlagh HR, et al. Long non-coding RNA HOTAIR induces the PI3K/AKT/mTOR signaling pathway in breast cancer cells. Rev Assoc Med Bras. 2022;68:456-62.
49. Jiang Y, Qian T, Li S, Xie Y, Tao M. Metformin reverses tamoxifen resistance through the lncRNA GAS5-medicated mTOR pathway in breast cancer. Ann Transl Med. 2022;10:366.
50. Xiao C, Wu CH, Hu HZ. LncRNA UCA1 promotes epithelial-mesenchymal transition (EMT) of breast cancer cells via enhancing Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2016;20:2819-24.
51. Liu H, Wang G, Yang L, Qu J, Yang Z, Zhou X. Knockdown of long non-coding RNA UCA1 increases the tamoxifen sensitivity of breast cancer cells through inhibition of Wnt/β-catenin pathway. PLoS One. 2016;11:e0168406.
52. Huang H, Jin H, Lei R, et al. lncRNA-WAL promotes triple-negative breast cancer aggression by inducing β-catenin nuclear translocation. Mol Cancer Res. 2024;22:1036-50.
53. Dashti S, Ghafouri-Fard S, Esfandi F, Oskooei VK, Arsang-Jang S, Taheri M. Expression analysis of NF-κB interacting long noncoding RNAs in breast cancer. Exp Mol Pathol. 2020;112:104359.
54. Liu B, Sun L, Liu Q, et al. A cytoplasmic NF-κB interacting long noncoding RNA blocks IκB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015;27:370-81.
55. Xu Y, Ren W, Li Q, et al. LncRNA Uc003xsl.1-mediated activation of the NFκB/IL8 axis promotes progression of triple-negative breast cancer. Cancer Res. 2022;82:556-70.
56. Zhang D, Ding X, Peng M. LncRNA SNHG14 accelerates breast cancer progression through sponging miR-543 and regulating KLF7 expression. Arch Gynecol Obstet. 2022;305:1507-16.
57. Xie SD, Qin C, Jin LD, et al. Long noncoding RNA SNHG14 promotes breast cancer cell proliferation and invasion via sponging miR-193a-3p. Eur Rev Med Pharmacol Sci. 2019;23:2461-8.
58. Zhang Y, Li Z, Chen M, et al. lncRNA TCL6 correlates with immune cell infiltration and indicates worse survival in breast cancer. Breast Cancer. 2020;27:573-85.
59. Adewunmi O, Shen Y, Zhang XH, Rosen JM. Targeted inhibition of lncRNA malat1 alters the tumor immune microenvironment in preclinical syngeneic mouse models of triple-negative breast cancer. Cancer Immunol Res. 2023;11:1462-79.
60. Desai P, Thumma NJ, Wagh PR, et al. Cancer chemoprevention using nanotechnology-based approaches. Front Pharmacol. 2020;11:323.
61. Zhang X, Xie K, Zhou H, et al. Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol Cancer. 2020;19:47.
62. Trayes KP, Cokenakes SEH. Breast cancer treatment. Am Fam Phys. 2021;104:171-8. Available from: https://www.aafp.org/pubs/afp/issues/2021/0800/p171.html [Last accessed on 4 Dec 2025].
63. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750-69.
64. Breast Cancer Trialists' Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393:1440-52.
65. Ahmed Khalil A, Rauf A, Alhumaydhi FA, et al. Recent developments and anticancer therapeutics of paclitaxel: an update. Curr Pharm Des. 2022;28:3363-73.
66. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253-65.
67. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003;66:1022-37.
68. Yan L, Yang S, Yue CX, et al. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells. Environ Toxicol. 2020;35:1015-28.
69. Xing Z, Zhang M, Liu J, Liu G, Feng K, Wang X. LINC00337 induces tumor development and chemoresistance to paclitaxel of breast cancer by recruiting M2 tumor-associated macrophages. Mol Immunol. 2021;138:1-9.
70. Gu M, Zheng W, Zhang M, et al. LncRNA NONHSAT141924 promotes paclitaxel chemotherapy resistance through p-CREB/Bcl-2 apoptosis signaling pathway in breast cancer. J Cancer. 2020;11:3645-54.
71. Zhu M, Wang F, Mi H, et al. Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells. Cell Cycle. 2020;19:3277-88.
72. Zheng S, Li M, Miao K, Xu H. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling. J Cell Biochem. 2020;121:2225-35.
73. Zhao T, Zhang T, Zhang Y, Zhou B, Lu X. Paclitaxel resistance modulated by the interaction between TRPS1 and AF178030.2 in triple-negative breast cancer. Evid Based Complement Alternat Med. 2022;2022:6019975.
74. Zheng P, Dong L, Zhang B, et al. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19. Histochem Cell Biol. 2019;152:281-91.
75. Liang M, Zhu B, Wang M, Jin J. Knockdown of long non-coding RNA DDX11-AS1 inhibits the proliferation, migration and paclitaxel resistance of breast cancer cells by upregulating microRNA-497 expression. Mol Med Rep. 2022;25:123.
76. Wang R, Zhang T, Yang Z, Jiang C, Seng J. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1. J Cell Mol Med. 2018;22:4068-75.
77. Luo F, Zhang M, Sun B, et al. LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling. Mol Cancer. 2024;23:60.
78. Wu H, Gu J, Zhou D, et al. LINC00160 mediated paclitaxel-and doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ. J Cell Mol Med. 2020;24:8589-602.
79. Shi C, Ren S, Zhao X, Li Q. lncRNA MALAT1 regulates the resistance of breast cancer cells to paclitaxel via the miR-497-5p/SHOC2 axis. Pharmacogenomics. 2022;23:973-85.
80. Wei X, Tao S, Mao H, et al. Exosomal lncRNA NEAT1 induces paclitaxel resistance in breast cancer cells and promotes cell migration by targeting miR-133b. Gene. 2023;860:147230.
81. Zhu L, Wang F, Fan W, Jin Z, Teng C, Zhang J. lncRNA NEAT1 promotes the Taxol resistance of breast cancer via sponging the miR-23a-3p-FOXA1 axis. Acta Biochim Biophys Sin. 2021;53:1198-206.
82. Li PP, Li RG, Huang YQ, Lu JP, Zhang WJ, Wang ZY. LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability. Aging. 2021;13:24171-91.
83. Zheng S, Fu W, Huang Q, et al. LncRNA PRKCQ-AS1 regulates paclitaxel resistance in triple-negative breast cancer cells through miR-361-5p/PIK3C3 mediated autophagy. Clin Exp Pharmacol Physiol. 2023;50:431-42.
84. Liu C, Jiang F, Zhang X, Xu X. Long non-coding RNA UCA1 modulates paclitaxel resistance in breast cancer via miR-613/CDK12 axis. Cancer Manag Res. 2020;12:2777-88.
85. Wang Y, Pei W, Yang Y, et al. Inhibition of XIST restrains paclitaxel resistance in breast cancer cells by targeting hsa-let-7d-5p/ATG16L1 through regulation of autophagy. Cell Signal. 2025;127:111534.
86. Wang YY, Yan L, Yang S, et al. Long noncoding RNA AC073284.4 suppresses epithelial-mesenchymal transition by sponging miR-18b-5p in paclitaxel-resistant breast cancer cells. J Cell Physiol. 2019;234:23202-15.
87. Huang Y, Zheng Y, Shao X, Shi L, Li G, Huang P. Long non-coding RNA TPT1-AS1 sensitizes breast cancer cell to paclitaxel and inhibits cell proliferation by miR-3156-5p/caspase 2 axis. Hum Cell. 2021;34:1244-54.
88. Arcamone F, Cassinelli G, Fantini G, et al. Adriamycin, 14-Hydroxydaunomycin, a new antitumor antibiotic fromS. peucetius var.caesius. Biotechnol Bioeng. 2000;67:704-13.
89. Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genom. 2011;21:440-6.
90. Renu K, V G A, P B TP, Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy - an update. Eur J Pharmacol. 2018;818:241-53.
91. Lefrak EA, Piťha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302-14.
92. Zhang M, Wang Y, Jiang L, et al. LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway. J Exp Clin Cancer Res. 2021;40:41.
93. Tang L, Chen Y, Chen H, et al. DCST1-AS1 promotes TGF-β-induced epithelial-mesenchymal transition and enhances chemoresistance in triple-negative breast cancer cells via ANXA1. Front Oncol. 2020;10:280.
94. Luo Y, Zhang W, Xu L, Chen Y, Xu Y, Yuan L. Long non-coding RNA PVT1 regulates the resistance of the breast cancer cell line MDA-MB-231 to doxorubicin via Nrf2. Technol Cancer Res Treat. 2020;19:1533033820980763.
95. Aini S, Bolati S, Ding W, et al. LncRNA SNHG10 suppresses the development of doxorubicin resistance by downregulating miR-302b in triple-negative breast cancer. Bioengineered. 2022;13:11430-9.
96. Gooding AJ, Zhang B, Gunawardane L, Beard A, Valadkhan S, Schiemann WP. The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers. Oncogene. 2019;38:2020-41.
97. Ren R, Yuan Z, Xu Z. miRNA-144 targeting DNAJC3-AS1 reverses the resistance of the breast cancer cell line Michigan Cancer Foundation-7 to doxorubicin. Bioengineered. 2021;12:9885-92.
98. Zhu QN, Wang G, Guo Y, et al. LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway. Oncotarget. 2017;8:91990-2003.
99. Chang L, Hu Z, Zhou Z, Zhang H. Linc00518 contributes to multidrug resistance through regulating the MiR-199a/MRP1 axis in breast cancer. Cell Physiol Biochem. 2018;48:16-28.
100. Li Z, Li Y, Wang X, et al. LINC01977 promotes breast cancer progression and chemoresistance to doxorubicin by targeting miR-212-3p/GOLM1 axis. Front Oncol. 2021;11:657094.
101. Zheng R, Jia J, Guan L, et al. Long noncoding RNA lnc-LOC645166 promotes adriamycin resistance via NF-κB/GATA3 axis in breast cancer. Aging. 2020;12:8893-912.
102. Yue X, Wu WY, Dong M, Guo M. LncRNA MALAT1 promotes breast cancer progression and doxorubicin resistance via regulating miR-570-3p. Biomed J. 2021;44:S296-304.
103. Jin YP, Xu BJ, Zhang XF, et al. Long non-coding RNA STMN1P2 promotes breast cancer doxorubicin resistance by inhibiting pyroptosis through the hnRNPU-EZH2-TARF6-MALT1-caspase-1 pathway. Acta Pharmacol Sin. 2025:1-15.
104. Wang S, Cheng M, Zheng X, et al. Interactions between lncRNA TUG1 and miR-9-5p modulate the resistance of breast cancer cells to doxorubicin by regulating eIF5A2. Onco Targets Ther. 2020;13:13159-70.
105. Zhang M, Wang F, Xiang Z, Huang T, Zhou WB. LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN. Clin Exp Pharmacol Physiol. 2020;47:1464-72.
106. Lu Q, Chen W, Ji Y, Liu Y, Xue X. Ursolic acid enhances cytotoxicity of doxorubicin-resistant triple-negative breast cancer cells via ZEB1-AS1/miR-186-5p/ABCC1 axis. Cancer Biother Radiopharm. 2022;37:673-83.
108. Minckwitz G. Docetaxel/anthracycline combinations for breast cancer treatment. Expert Opin Pharmacother. 2007;8:485-95.
109. Zhang C, Wang J, Zhang J, Qu H, Tang X. LINC00461 overexpression can induce docetaxel resistance in breast cancer by interacting with miR-411-5p. Onco Targets Ther. 2020;13:5551-62.
110. Ning X, Zhao J, He F, Yuan Y, Li B, Ruan J. Long non-coding RNA TMPO-AS1 facilitates chemoresistance and invasion in breast cancer by modulating the miR-1179/TRIM37 axis. Oncol Lett. 2021;22:500.
111. Li J, Kang J, Liu W, et al. Docetaxel-resistant triple-negative breast cancer cell-derived exosomal lncRNA LINC00667 reduces the chemosensitivity of breast cancer cells to docetaxel via targeting miR-200b-3p/Bcl-2 axis. Eur J Histochem. 2022:66.
112. Duan H, Liu Y, Gao Z, Huang W. Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharm Sin B. 2021;11:55-70.
113. Levine M. Epirubicin in breast cancer: present and future. Clin Breast Cancer. 2000;1 Suppl 1:S62-7.
114. Yao N, Fu Y, Chen L, et al. Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis. Oncogene. 2019;38:7216-33.
115. Zheng A, Zhang L, Song X, Jin F. Clinical significance of SPRY4-IT1 in efficacy and survival prediction in breast cancer patients undergoing neoadjuvant chemotherapy. Histol Histopathol. 2020;35:361-70.
116. Wang F, Yang S, Lv M, et al. Novel long noncoding RNA 005620 induces epirubicin resistance in triple-negative breast cancer by regulating ITGB1 expression. Front Oncol. 2021;11:592215.
117. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179:663-6.
118. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330-8.
119. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16:215-37.
120. Li X, Wang S, Li Z, et al. The lncRNA NEAT1 facilitates cell growth and invasion via the miR-211/HMGA2 axis in breast cancer. Int J Biol Macromol. 2017;105:346-53.
121. Liang Y, Song X, Li Y, et al. A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer. Cell Death Dis. 2018;9:563.
122. Zhang Z, Wang X, Wang Y, et al. Effect of long noncoding RNA CCAT2 on drug sensitivity to 5-fluorouracil of breast cancer cells through microRNA-145 meditated by p53. J Biochem Mol Toxicol. 2022;36:e23176.
123. Luo L, Zhang J, Tang H, et al. LncRNA SNORD3A specifically sensitizes breast cancer cells to 5-FU by sponging miR-185-5p to enhance UMPS expression. Cell Death Dis. 2020;11:329.
124. Yang W, Gu J, Wang X, et al. Inhibition of circular RNA CDR1as increases chemosensitivity of 5-FU-resistant BC cells through up-regulating miR-7. J Cell Mol Med. 2019;23:3166-77.
125. Yao X, Tu Y, Xu Y, Guo Y, Yao F, Zhang X. Endoplasmic reticulum stress confers 5-fluorouracil resistance in breast cancer cell via the GRP78/OCT4/lncRNA MIAT/AKT pathway. Am J Cancer Res. 2020;10:838-55.
126. Villarreal-Garza C, Khalaf D, Bouganim N, et al. Platinum-based chemotherapy in triple-negative advanced breast cancer. Breast Cancer Res Treat. 2014;146:567-72.
127. Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869-83.
128. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573-84.
129. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;222:385-6.
130. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-78.
131. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265-79.
132. Zhou L, Li H, Sun T, et al. HULC targets the IGF1R-PI3K-AKT axis in trans to promote breast cancer metastasis and cisplatin resistance. Cancer Lett. 2022;548:215861.
133. Su A, Yao K, Zhang H, Wang Y, Zhang H, Tang J. DANCR induces cisplatin resistance of triple-negative breast cancer by KLF5/p27 signaling. Am J Pathol. 2023;193:248-58.
134. García-Venzor A, Mandujano-Tinoco EA, Ruiz-Silvestre A, et al. lncMat2B regulated by severe hypoxia induces cisplatin resistance by increasing DNA damage repair and tumor-initiating population in breast cancer cells. Carcinogenesis. 2020;41:1485-97.
135. Tang T, Cheng Y, She Q, et al. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer. Biomed Pharmacother. 2018;107:338-46.
136. Sheng X, Dai H, Du Y, et al. LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication. J Exp Clin Cancer Res. 2021;40:205.
137. Wu J, Xu W, Ma L, et al. Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer. Aging. 2021;13:18191-222.
138. Wu J, Chen H, Ye M, et al. Long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression. Biomed Pharmacother. 2019;115:108869.
139. Wu B, Yuan Y, Han X, et al. Structure of LINC00511-siRNA-conjugated nanobubbles and improvement of cisplatin sensitivity on triple negative breast cancer. FASEB J. 2020;34:9713-26.
140. Zhou D, Gu J, Wang Y, et al. Long non-coding RNA NEAT1 transported by extracellular vesicles contributes to breast cancer development by sponging microRNA-141-3p and regulating KLF12. Cell Biosci. 2021;11:68.
141. Zhang L, Zhang J, Ni C. Silencing of lncRNA PART1 inhibits proliferation, invasion and migration of breast cancer cells and promotes the efficacy of cisplatin in breast cancer cells. Gen Physiol Biophys. 2020;39:343-54.
142. Zhang M, Yang L, Hou L, Tang X. LncRNA SNHG1 promotes tumor progression and cisplatin resistance through epigenetically silencing miR-381 in breast cancer. Bioengineered. 2021;12:9239-50.
143. Mi H, Wang X, Wang F, et al. SNHG15 contributes To cisplatin resistance in breast cancer through sponging miR-381. Onco Targets Ther. 2020;13:657-66.
144. Zhu M, Xiang H, Peng Z, et al. Silencing the expression of lncRNA SNHG15 may be a novel therapeutic approach in human breast cancer through regulating miR-345-5p. Ann Transl Med. 2022;10:1173.
145. Zhu D, Zhang X, Lin Y, Liang S, Song Z, Dong C. MT1JP inhibits tumorigenesis and enhances cisplatin sensitivity of breast cancer cells through competitively binding to miR-24-3p. Am J Transl Res. 2019;11:245-56.
146. Sella T, Weiss A, Mittendorf EA, et al. Neoadjuvant endocrine therapy in clinical practice: a review. JAMA Oncol. 2021;7:1700-8.
147. Hasson S, Brezis MR, Shachar E, Shachar SS, Wolf I, Sonnenblick A. Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis. ESMO Open. 2021;6:100088.
148. Ballinger TJ, Meier JB, Jansen VM. Current landscape of targeted therapies for hormone-receptor positive, HER2 negative metastatic breast cancer. Front Oncol. 2018;8:308.
149. Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell. 2020;37:496-513.
150. AlFakeeh A, Brezden-Masley C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr Oncol. 2018;25:S18-27.
152. Barchiesi G, Mazzotta M, Krasniqi E, et al. Neoadjuvant endocrine therapy in breast cancer: current knowledge and future perspectives. Int J Mol Sci. 2020;21:3528.
154. Shi Q, Li Y, Li S, et al. LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer. Nat Commun. 2020;11:5513.
155. Wang J, Xie S, Yang J, et al. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy. J Hematol Oncol. 2019;12:81.
156. Lin X, Dinglin X, Cao S, et al. Enhancer-driven lncRNA BDNF-AS induces endocrine resistance and malignant progression of breast cancer through the RNH1/TRIM21/mTOR cascade. Cell Rep. 2020;31:107753.
157. Xue X, Yang YA, Zhang A, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2016;35:2746-55.
158. Li Z, Yu D, Li H, Lv Y, Li S. Long non-coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. Int J Oncol. 2019;54:1033-42.
159. Shi YF, Lu H, Wang HB. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p. Eur Rev Med Pharmacol Sci. 2019;23:1563-73.
160. Barazetti JF, Jucoski TS, Carvalho TM, et al. From micro to long: non-coding RNAs in tamoxifen resistance of breast cancer cells. Cancers. 2021;13:3688.
161. Farhan M, Aatif M, Dandawate P, Ahmad A. Non-coding RNAs as mediators of tamoxifen resistance in breast cancers. In: Ahmad A, editor. Breast cancer metastasis and drug resistance. Cham: Springer International Publishing; 2019. pp. 229-41.
162. Yu S, Wang Y, Gong X, et al. LncRNA AGPG confers endocrine resistance in breast cancer by promoting E2F1 activity. Cancer Res. 2023;83:3220-36.
163. Zhang H, Zhang J, Dong L, Ma R. LncRNA ATXN8OS enhances tamoxifen resistance in breast cancer. Open Med. 2021;16:68-80.
164. Horie K, Takagi K, Takeiwa T, et al. Estrogen-inducible LncRNA BNAT1 functions as a modulator for estrogen receptor signaling in endocrine-resistant breast cancer cells. Cells. 2022;11:3610.
165. Liu Y, Li M, Yu H, Piao H. lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR-125a-5p. Int J Mol Med. 2020;45:497-509.
166. Liang X, Zhao Y, Fang Z, et al. DLGAP1-AS2 promotes estrogen receptor signalling and confers tamoxifen resistance in breast cancer. Mol Biol Rep. 2022;49:3939-47.
167. Ma Y, Bu D, Long J, Chai W, Dong J. LncRNA DSCAM-AS1 acts as a sponge of miR-137 to enhance Tamoxifen resistance in breast cancer. J Cell Physiol. 2019;234:2880-94.
168. Ren L, Zhou H, Lei L, Zhang Y, Cai H, Wang X. Long non-coding RNA FOXD3 antisense RNA 1 augments anti-estrogen resistance in breast cancer cells through the microRNA-363/trefoil factor 1/phosphatidylinositol 3-kinase/protein kinase B axis. Bioengineered. 2021;12:5266-78.
169. Li Y, Liu L, Lv Y, et al. Silencing long non-coding RNA HNF1A-AS1 inhibits growth and resistance to TAM of breast cancer cells via the microRNA-363/SERTAD3 axis. J Drug Target. 2021;29:742-53.
170. Kim CY, Oh JH, Lee JY, Kim MH. The LncRNA HOTAIRM1 promotes tamoxifen resistance by mediating HOXA1 expression in ER+ breast cancer cells. J Cancer. 2020;11:3416-23.
171. Lee J, Kang B, Kim EA, et al. Differential expression of long non-coding RNA IGF2-as in tamoxifen-resistant breast cancer cells. Biomedicines. 2025;13:2087.
172. Peng WX, Koirala P, Zhou H, et al. Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer. Cell Death Dis. 2021;12:1000.
173. Liao M, Webster J, Coonrod EM, Weilbaecher KN, Maher CA, White NM. BCAR4 expression as a predictive biomarker for endocrine therapy resistance in breast cancer. Clin Breast Cancer. 2024;24:368-75.e2.
174. Chen X, Ding JC, Hu GS, et al. Estrogen-induced LncRNA, LINC02568, promotes estrogen receptor-positive breast cancer development and drug resistance through both in trans and in cis mechanisms. Adv Sci. 2023;10:e2206663.
175. Ma T, Liang Y, Li Y, et al. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer. Cell Signal. 2020;68:109536.
176. Sun W, Xu X, Jiang Y, et al. Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance. Int J Cancer. 2019;145:842-56.
177. Feng J, Wen T, Li Z, et al. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance. Aging. 2020;12:20658-83.
178. Wu C, Sun X, Lu Y, et al. Cancer-associated fibroblast promotes tamoxifen resistance in estrogen receptor positive breast cancer via exosomal LncRNA PRKCQ-AS1/miR-200a-3p/MKP1 axis-mediated apoptosis suppression. J Exp Clin Cancer Res. 2025;44:274.
179. Peng WX, Huang JG, Yang L, Gong AH, Mo YY. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer. Mol Cancer. 2017;16:161.
180. Khan MI, Ahmad A. LncRNA SNHG6 sponges miR-101 and induces tamoxifen resistance in breast cancer cells through induction of EMT. Front Oncol. 2022;12:1015428.
181. Fang J, Li K, Huang C, Xue H, Ni Q. LncRNA TTN-AS1 confers tamoxifen resistance in breast cancer via sponging miR-107 to modulate PI3K/AKT signaling pathway. Am J Transl Res. 2022;14:2267-79.
182. Ratre P, Mishra K, Dubey A, Vyas A, Jain A, Thareja S. Aromatase inhibitors for the treatment of breast cancer: a journey from the scratch. Anticancer Agents Med Chem. 2020;20:1994-2004.
183. Sood A, Lang DK, Kaur R, Saini B, Arora S. Relevance of aromatase inhibitors in breast cancer treatment. Curr Top Med Chem. 2021;21:1319-36.
184. Nagini S. Breast cancer: current molecular therapeutic targets and new players. Anticancer Agents Med Chem. 2017;17:152-63.
185. Chen X, Luo R, Zhang Y, et al. Long noncoding RNA DIO3OS induces glycolytic-dominant metabolic reprogramming to promote aromatase inhibitor resistance in breast cancer. Nat Commun. 2022;13:7160.
186. Huang S, Chi Y, Chi W, et al. LINC00309 is associated with short disease-free survival in breast cancer. Cancer Cell Int. 2019;19:210.
187. Ingle JN, Xie F, Ellis MJ, et al. Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy. Cancer Res. 2016;76:7012-23.
188. Gu G, Dustin D, Fuqua SA. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr Opin Pharmacol. 2016;31:97-103.
189. Schlam I, Tarantino P, Morganti S, et al. Emerging targeted therapies for early breast cancer. Drugs. 2022;82:1437-51.
190. Lau KH, Tan AM, Shi Y. New and emerging targeted therapies for advanced breast cancer. Int J Mol Sci. 2022;23:2288.
191. Greenwalt I, Zaza N, Das S, Li BD. Precision medicine and targeted therapies in breast cancer. Surg Oncol Clin N Am. 2020;29:51-62.
192. Jacobs AT, Martinez Castaneda-Cruz D, Rose MM, Connelly L. Targeted therapy for breast cancer: an overview of drug classes and outcomes. Biochem Pharmacol. 2022;204:115209.
193. Clarke R, Tyson JJ, Dixon JM. Endocrine resistance in breast cancer-an overview and update. Mol Cell Endocrinol. 2015;418 Pt 3:220-34.
195. Curigliano G, Criscitiello C. Successes and limitations of targeted cancer therapy in breast cancer. In: Peters S, Stahel R, editors. Successes and limitations of targeted cancer therapy; 2014. pp. 15-35.
196. Henriques B, Mendes F, Martins D. Immunotherapy in breast cancer: when, how, and what challenges? Biomedicines. 2021;9:1687.
197. Wang ZH, Zheng ZQ, Jia SC, et al. Trastuzumab resistance in HER2-positive breast cancer: mechanisms, emerging biomarkers and targeting agents. Front Oncol. 2022;12:1006429.
198. Ghafouri-Fard S, Tamizkar KH, Hussen BM, Taheri M. An update on the role of long non-coding RNAs in the pathogenesis of breast cancer. Pathol Res Pract. 2021;219:153373.
199. Dong H, Wang W, Mo S, et al. Long non-coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation. J Cell Mol Med. 2018;22:4935-47.
200. Zhu HY, Bai WD, Ye XM, Yang AG, Jia LT. Long non-coding RNA UCA1 desensitizes breast cancer cells to trastuzumab by impeding miR-18a repression of Yes-associated protein 1. Biochem Biophys Res Commun. 2018;496:1308-13.
201. Ghazimoradi MH, Babashah S. The role of CircRNA/miRNA/mRNA axis in breast cancer drug resistance. Front Oncol. 2022;12:966083.
202. Zou Y, Yang A, Chen B, et al. crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer. Drug Resist Updat. 2024;77:101126.
203. Misir S, Yaman SO, Petrović N, Sumer C, Hepokur C, Aliyazicioglu Y. circRNAs in drug resistance of breast cancer. Oncol Res. 2022;30:157-72.
204. Guo J, Li K, Ming Y, et al. A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC. Proc Natl Acad Sci USA. 2025;122:e2504320122.
205. Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 2015;6:11652-63.
206. Song X, Liu S, Zeng Y, Cai Y, Luo H. BANCR-containing extracellular vesicles enhance breast cancer resistance. J Biol Chem. 2025;301:108304.
207. Ye X, Liu Q, Qin X, et al. BCAR4 facilitates trastuzumab resistance and EMT in breast cancer via sponging miR-665 and interacting with YAP1. FASEB J. 2024;38:e23589.
208. Sun Z, Zhang C, Wang T, Shi P, Tian X, Guo Y. Correlation between long non-coding RNAs (lncRNAs) H19 expression and trastuzumab resistance in breast cancer. J Cancer Res Ther. 2019;15:933-40.
209. Chen T, Liu Z, Zeng W, Huang T. Down-regulation of long non-coding RNA HOTAIR sensitizes breast cancer to trastuzumab. Sci Rep. 2019;9:19881.
210. Bai W, Peng H, Zhang J, et al. LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2+ breast cancer. NPJ Breast Cancer. 2022;8:115.
211. Liu C, Lu C, Yixi L, et al. Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing HER-2 protein expression and mRNA stability by binding to HUR. Breast Cancer Res. 2023;25:124.
212. Yu Q, Li Y, Peng S, Li J, Qin X. Exosomal-mediated transfer of OIP5-AS1 enhanced cell chemoresistance to trastuzumab in breast cancer via up-regulating HMGB3 by sponging miR-381-3p. Open Med. 2021;16:512-25.
213. Han M, Qian X, Cao H, et al. lncRNA ZNF649-AS1 induces trastuzumab resistance by promoting ATG5 expression and autophagy. Mol Ther. 2020;28:2488-502.
214. Dong H, Han J, Chen X, Sun H, Han M, Wang W. LncRNA ZNF649-AS1 promotes trastuzumab resistance and TAM-dependent PD-L1 expression in breast cancer by regulating EXOC7 alternative splicing. Arch Biochem Biophys. 2024;761:110128.
215. Li W, Zhai L, Wang H, et al. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer. Oncotarget. 2016;7:27778-86.
216. Convit J, Montesinos H, Oviedo H, et al. Autologous tumor lysate/Bacillus Calmette-Guérin immunotherapy as an adjuvant to conventional breast cancer therapy. Clin Transl Oncol. 2015;17:884-7.
217. Morales MA, Barrera Rodríguez R, Santiago Cruz JR, Teran LM. Overview of new treatments with immunotherapy for breast cancer and a proposal of a combination therapy. Molecules. 2020;25:5686.
218. Pilipow K, Darwich A, Losurdo A. T-cell-based breast cancer immunotherapy. Semin Cancer Biol. 2021;72:90-101.
219. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108-21.
220. Jia H, Truica CI, Wang B, et al. Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects. Drug Resist Updat. 2017;32:1-15.
221. Li S, Sun X, Li J, et al. A novel prognostic signature of immune-related long noncoding RNA pairs for tumor-infiltrating immune cells and drug susceptibility in breast cancer. DNA Cell Biol. 2022;41:103-15.
222. Shen S, Chen X, Hu X, Huo J, Luo L, Zhou X. Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune-related lncRNA. Cancer Med. 2021;10:6561-75.
223. Xu Y, Zheng Q, Zhou T, Ye B, Xu Q, Meng X. Necroptosis-related LncRNAs signature and subtypes for predicting prognosis and revealing the immune microenvironment in breast cancer. Front Oncol. 2022;12:887318.
224. Zhang X, Zhang X, Li G, et al. A novel necroptosis-associated lncRNA signature can impact the immune status and predict the outcome of breast cancer. J Immunol Res. 2022;2022:3143511.
225. Zhang D, Lu W, Zhuo Z, Wang Y, Zhang W, Zhang M. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer. BMC Med Genomics. 2023;16:96.
226. Liao B, Wang J, Xie Y, Luo H, Min J. LINK-A: unveiling its functional role and clinical significance in human tumors. Front Cell Dev Biol. 2024;12:1354726.
227. Hu Q, Ye Y, Chan LC, et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019;20:835-51.
228. Lian B, Li J, Tang S, Li T, Li J. Targeting LINC02544/miR-497-5p/CAPRIN1 axis via exosome-based siRNA to overcome immunotherapy resistance in triple-negative breast cancer. Mol Med. 2025;31:278.
229. Sun C, Ye Y, Tan Z, et al. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Sci Adv. 2023;9:eadd6995.
230. Famta P, Shah S, Khatri DK, Guru SK, Singh SB, Srivastava S. Enigmatic role of exosomes in breast cancer progression and therapy. Life Sci. 2022;289:120210.
231. Rezaee M, Mohammadi F, Keshavarzmotamed A, et al. The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms. Front Pharmacol. 2023;14:1152672.
232. Huang D, Chen J, Yang L, et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol. 2018;19:1112-25.
233. Pei X, Wang X, Li H. LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO. Int J Biol Macromol. 2018;118:24-30.
234. Yang H, Qi C, Li B, Cheng L. Non-coding RNAs as novel biomarkers in cancer drug resistance. Curr Med Chem. 2022;29:837-48.
235. Wu J, Zhang C, Li H, Zhang S, Chen J, Qin L. Competing endogenous RNAs network dysregulation in oral cancer: a multifaceted perspective on crosstalk and competition. Cancer Cell Int. 2024;24:431.
236. To KKW, Zhang H, Cho WC. Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy. Cancer Drug Resist. 2024;7:37.
237. Wu B, Zhang Y, Yu Y, et al. Long noncoding RNA H19: a novel therapeutic target emerging in oncology via regulating oncogenic signaling pathways. Front Cell Dev Biol. 2021;9:796740.
238. Su WY, Tian LY, Guo LP, Huang LQ, Gao WY. PI3K signaling-regulated metabolic reprogramming: from mechanism to application. Biochim Biophys Acta Rev Cancer. 2023;1878:188952.
239. Cirone M. Cancer cells dysregulate PI3K/AKT/mTOR pathway activation to ensure their survival and proliferation: mimicking them is a smart strategy of gammaherpesviruses. Crit Rev Biochem Mol Biol. 2021;56:500-9.
240. Raju GSR, Pavitra E, Bandaru SS, et al. HOTAIR: a potential metastatic, drug-resistant and prognostic regulator of breast cancer. Mol Cancer. 2023;22:65.
241. Barwal TS, Sharma U, Bazala S, et al. MicroRNAs and long noncoding RNAs as novel therapeutic targets in estrogen receptor-positive breast and ovarian cancers. Int J Mol Sci. 2021;22:4072.
242. Hu X, Zhang Q, Xing W, Wang W. Role of microRNA/lncRNA intertwined with the Wnt/β-Catenin axis in regulating the pathogenesis of triple-negative breast cancer. Front Pharmacol. 2022;13:814971.
243. Ebrahimnezhad M, Asl SH, Rezaie M, Molavand M, Yousefi B, Majidinia M. lncRNAs: new players of cancer drug resistance via targeting ABC transporters. IUBMB Life. 2024;76:883-921.
244. Rembiałkowska N, Kocik Z, Kłosińska A, et al. Inflammation-driven genomic instability: a pathway to cancer development and therapy resistance. Pharmaceuticals. 2025;18:1406.
245. Han C, Zhang C, Wang H, Zhao L. Exosome-mediated communication between tumor cells and tumor-associated macrophages: implications for tumor microenvironment. Oncoimmunology. 2021;10:1887552.
